THYMOGLOBULIN Market Summary

Key Factors Driving THYMOGLOBULIN Growth

1. Growing kidney-transplant volumes: THYMOGLOBULIN (anti-thymocyte globulin [rabbit]) is FDA-approved for prophylaxis and treatment of acute rejection in adult and pediatric kidney-transplant recipients, creating a direct demand base linked to transplant activity. More than 49,000 organ transplants were performed in the U.S. in 2025, supporting continued demand for induction and rejection-management therapies.

2. Strong and growing commercial performance: Sanofi reported €124 million in THYMOGLOBULIN sales in 2025, representing 6.4% growth, primarily driven by higher U.S. sales. This indicates continued commercial momentum despite the product's mature lifecycle.

3. Expansion across international markets: International demand is an important contributor to growth. In H1 2025, THYMOGLOBULIN sales reached €248 million, up 2.4% at constant exchange rates, with growth driven by the Rest of the World region. In Q2 2025, sales were €126 million, up 2.3%, reflecting higher sales in both the U.S. and Europe.

4. Established role in transplant immunosuppression: THYMOGLOBULIN produces broad T-cell depletion, supporting its use as part of immunosuppressive regimens around kidney transplantation. Its established clinical experience and long-standing presence in transplantation can support continued physician adoption, particularly where reduction of acute rejection risk is a treatment priority.

5. Potential utilization in hematopoietic stem-cell transplantation: Although the FDA-approved THYMOGLOBULIN indication is kidney transplantation, rabbit ATG—including THYMOGLOBULIN—is also used in allogeneic hematopoietic stem-cell transplantation to reduce graft-versus-host disease (GVHD). Published literature describes its role in GVHD prophylaxis, while clinical studies have reported reductions in acute and chronic GVHD with ATG-containing regimens. This broader clinical utilization can contribute to demand beyond the labeled kidney-transplant indication.

THYMOGLOBULIN Recent Developments

In November 2024, Sanofi announced a €40 million ($42.46 million) investment to enhance its biomanufacturing capabilities at the Lyon Gerland site in France.

The initiative aims to bolster the production of Thymoglobulin (antithymocyte globulin [rabbit]), a treatment for kidney transplant rejection, and to localize the manufacturing of type 1 diabetes therapy Tzield (teplizumab).

“THYMOGLOBULIN Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of THYMOGLOBULIN for approved indication like Aplastic anaemia, Bone marrow transplant rejection, Graft-versus-host disease, Liver transplant rejection; as well as potential indication like Heart transplant rejection, Myelodysplastic syndromes, and Type 1 diabetes mellitus in the 7MM. A detailed picture of THYMOGLOBULIN’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the THYMOGLOBULIN for approved and potential indications. The THYMOGLOBULIN market report provides insights about THYMOGLOBULIN’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current THYMOGLOBULIN performance, future market assessments inclusive of the THYMOGLOBULIN market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of THYMOGLOBULIN sales forecasts, along with factors driving its market.

THYMOGLOBULIN Drug Summary

THYMOGLOBULIN is a polyclonal immunosuppressive biologic derived from rabbits immunized with human thymocytes and is designed to produce broad T-cell depletion and immunomodulation. It binds to multiple antigens expressed on human T lymphocytes, promoting their depletion through mechanisms including complement-dependent lysis and antibody-dependent cellular cytotoxicity, thereby suppressing cell-mediated immune responses. THYMOGLOBULIN is administered intravenously (IV) and is primarily used as part of immunosuppressive regimens for the prevention or treatment of acute rejection following kidney transplantation; it is also used in certain hematopoietic stem-cell transplantation settings and for the treatment of aplastic anemia, depending on the clinical regimen and jurisdiction. The drug is generally administered over several hours under close medical supervision because infusion-associated reactions, including fever, chills, hypotension, rash, and cytokine-release symptoms, can occur. Its prolonged immunosuppressive activity can also increase susceptibility to infections and may contribute to hematologic abnormalities such as leukopenia and thrombocytopenia. THYMOGLOBULIN is marketed by Sanofi and remains an established component of transplantation and immunosuppression protocols because of its broad T-cell–depleting activity and extensive clinical experience. The report provides THYMOGLOBULIN’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the THYMOGLOBULIN Market Report

The report provides insights into:

• A comprehensive product overview including the THYMOGLOBULIN MoA, description, dosage and administration, research and development activities in approved indications like Aplastic anaemia, Bone marrow transplant rejection, Graft-versus-host disease, Liver transplant rejection; as well as potential indication like Heart transplant rejection, Myelodysplastic syndromes, and Type 1 diabetes mellitus.
• Elaborated details on THYMOGLOBULIN regulatory milestones and other development activities have been provided in THYMOGLOBULIN market report.
• The report also highlights THYMOGLOBULIN‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The THYMOGLOBULIN market report also covers the patents information, generic entry and impact on cost cut.
• The THYMOGLOBULIN market report contains current and forecasted THYMOGLOBULIN sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The THYMOGLOBULIN market report also features the SWOT analysis with analyst views for THYMOGLOBULIN in approved and potential indications.

Methodology

The THYMOGLOBULIN market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

THYMOGLOBULIN Analytical Perspective by DelveInsight

• In-depth THYMOGLOBULIN Market Assessment

This THYMOGLOBULIN sales market forecast report provides a detailed market assessment of THYMOGLOBULIN for approved indication like Aplastic anaemia, Bone marrow transplant rejection, Graft-versus-host disease, Liver transplant rejection; as well as potential indication like Heart transplant rejection, Myelodysplastic syndromes, and Type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted THYMOGLOBULIN sales data uptil 2034.

• THYMOGLOBULIN Clinical Assessment

The THYMOGLOBULIN market report provides the clinical trials information of THYMOGLOBULIN for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

THYMOGLOBULIN Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

THYMOGLOBULIN Market Potential & Revenue Forecast

• Projected market size for the THYMOGLOBULIN and its key indications
• Estimated THYMOGLOBULIN sales potential (THYMOGLOBULIN peak sales forecasts)
• THYMOGLOBULIN Pricing strategies and reimbursement landscape

THYMOGLOBULIN Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• THYMOGLOBULIN Market positioning compared to existing treatments
• THYMOGLOBULIN Strengths & weaknesses relative to competitors

THYMOGLOBULIN Regulatory & Commercial Milestones

• THYMOGLOBULIN Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

THYMOGLOBULIN Clinical Differentiation

• THYMOGLOBULIN Efficacy & safety advantages over existing drugs
• THYMOGLOBULIN Unique selling points

THYMOGLOBULIN Market Report Highlights

• In the coming years, the THYMOGLOBULIN market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The THYMOGLOBULIN companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence THYMOGLOBULIN’s dominance.
• Other emerging products for Aplastic anaemia, Bone marrow transplant rejection, Graft-versus-host disease, Liver transplant rejection; as well as potential indication like Heart transplant rejection, Myelodysplastic syndromes, and Type 1 diabetes mellitus are expected to give tough market competition to THYMOGLOBULIN and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of THYMOGLOBULIN in approved and potential indications.
• Analyse THYMOGLOBULIN cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted THYMOGLOBULIN sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of THYMOGLOBULIN in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of THYMOGLOBULIN? How strong is THYMOGLOBULIN’s clinical and commercial performance?
• What is THYMOGLOBULIN’s clinical trial status in each individual indications such as Aplastic anaemia, Bone marrow transplant rejection, Graft-versus-host disease, Liver transplant rejection; as well as potential indication like Heart transplant rejection, Myelodysplastic syndromes, and Type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the THYMOGLOBULIN Manufacturers?
• What are the key designations that have been granted to THYMOGLOBULIN for approved and potential indications? How are they going to impact THYMOGLOBULIN’s penetration in various geographies?
• What is the current and forecasted THYMOGLOBULIN market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of THYMOGLOBULIN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to THYMOGLOBULIN for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is THYMOGLOBULIN? What is the duration of therapy and what are the geographical variations in cost per patient?